Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $221.9 million.

  • Allogene Therapeutics' Shares Outstanding (Weighted Average) rose 6.11% to $221.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.9 million, marking a year-over-year increase of 6.11%. This contributed to the annual value of $209.7 million for FY2024, which is 24.60% up from last year.
  • Allogene Therapeutics' Shares Outstanding (Weighted Average) amounted to $221.9 million in Q3 2025, which was up 1.44% from $218.7 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Shares Outstanding (Weighted Average) registered a high of $221.9 million during Q3 2025, and its lowest value of $140.6 million during Q1 2021.
  • In the last 3 years, Allogene Therapeutics' Shares Outstanding (Weighted Average) had a median value of $170.9 million in 2024 and averaged $185.7 million.
  • Data for Allogene Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 28.49% (in 2025) over the last 5 years.
  • Allogene Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $142.5 million in 2021, then rose by 1.19% to $144.2 million in 2022, then rose by 16.69% to $168.3 million in 2023, then climbed by 24.60% to $209.7 million in 2024, then increased by 6.11% to $221.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $221.9 million in Q3 2025, compared to $218.7 million in Q2 2025 and $217.3 million in Q1 2025.